8-K: Coherus BioSciences Amends Indenture, Repurchases $170 Million of Convertible Notes Amid UDENYCA Divestiture

Coherus BioSciences amends its indenture to facilitate the UDENYCA divestiture and repurchases $170 million of its convertible notes, with plans to repurchase the remaining $60 million after the divestiture closes.

Summary

• Coherus BioSciences has amended its indenture governing its 1.500% Convertible Senior Subordinated Notes due 2026.
• The amendment facilitates the previously announced divestiture of its UDENYCA franchise to Intas Pharmaceuticals Ltd.
• Coherus has repurchased approximately $170 million aggregate principal amount of the Convertible Notes at 100% of their principal amount, plus accrued and unpaid interest.
• The repurchases were privately negotiated with certain holders and are conditional upon the closing of the UDENYCA divestiture.
• Following the repurchases, approximately $60 million aggregate principal amount of Convertible Notes will remain outstanding.
• Coherus intends to conduct a repurchase offer for the remaining Convertible Notes after the divestiture closes, also at 100% of their principal amount plus accrued interest.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company is taking steps to streamline its operations and reduce debt, but the dependence on the UDENYCA divestiture closing introduces some uncertainty.

Positives

• The indenture amendment removes an obstacle to the UDENYCA divestiture.
• The repurchase of convertible notes reduces Coherus's debt obligations.
• The planned repurchase of remaining notes further streamlines the capital structure.
• The company is using proceeds from the UDENYCA sale to repurchase debt.

Risks

• The repurchase is contingent on the UDENYCA divestiture closing, which is subject to customary closing conditions.
• The company's ability to repay its indebtedness in the future depends on its financial performance.
• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Coherus intends to repurchase the remaining $60 million of convertible notes after the closing of the UDENYCA divestiture.

Industry Context

This announcement reflects a strategic shift for Coherus, focusing on its oncology pipeline and divesting its biosimilar business to streamline operations and reduce debt.

Comparison to Industry Standards

• Many companies in the biopharmaceutical industry use convertible notes as a financing tool.
• Repurchasing convertible notes is a common strategy to manage debt and reduce potential dilution.
• Divesting non-core assets is a typical move for companies to focus on strategic priorities.
• Comparable companies that have used similar strategies include Amgen and Biogen.

Stakeholder Impact

• Shareholders: Positive impact due to debt reduction and strategic focus.
• Employees: Potential impact due to the divestiture of UDENYCA.
• Creditors: Positive impact due to debt repurchase.
• Customers: Unlikely to be significantly impacted.

Next Steps

• Closing of the UDENYCA divestiture.
• Repurchase of the remaining $60 million of convertible notes.
• Continued development of the oncology pipeline.

Key Dates

Keywords

Coherus BioSciences, Convertible Notes, UDENYCA, Divestiture, Repurchase, Indenture, Intas Pharmaceuticals, Debt, LOQTORZI, Biosimilar